Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience Corp (TWST) reported that Chief Executive Officer and director Emily M. Leproust sold a total of 41,570 shares of common stock on August 25, 2026 in multiple open-market transactions under a previously adopted Rule 10b5-1 trading plan. The reported weighted average sale prices ranged from about $150.56 to $154.45 per share across the trades. Leproust also continues to hold several employee stock option positions, including performance stock options exercisable into 64,950 shares of common stock at an exercise price of $67.85 per share expiring on August 31, 2030.
Twist Bioscience Corp (TWST) is the issuer of common stock referenced in a Form 144 filed on behalf of Emily M. Leproust, with Fidelity Brokerage Services LLC involved as broker. The notice lists prior sales of common shares over the past three months on NASDAQ, including multiple sizable transactions with seven‑figure aggregate sale values.
Twist Bioscience Corp (TWST) reported an insider transaction by Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary. On 2026-08-21, he sold 1,598 shares of common stock at $139.066 per share. A footnote states these shares were sold under a mandated "sell to cover" arrangement to satisfy tax withholding obligations upon vesting of Restricted Stock Units, and are not discretionary trades. Following this transaction, Cho directly held 74,063 shares of Twist Bioscience common stock.
Twist Bioscience Corp (TWST) reported that President and COO Patrick John Finn sold 4,046 shares of common stock on 2026-08-21 at a price of $139.066 per share. According to the company’s equity incentive plan, this was a mandatory “sell to cover” transaction to satisfy tax withholding on vested Restricted Stock Units, not a discretionary trade. After this sale, Finn directly held 210,802 shares, including shares previously acquired under Twist Bioscience’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).
Twist Bioscience Corp (TWST) reported that officer Paula Green, SVP of Human Resources, had 1,360 shares of common stock sold on 2026-08-21 at $139.066 per share. According to the company’s equity incentive plan, this was a mandatory “sell to cover” transaction to satisfy tax withholding on vesting RSUs, not a discretionary trade. After this tax-related sale, Green directly holds 117,921 shares of Twist Bioscience common stock.
Twist Bioscience Corp (TWST) reported that its Chief Financial Officer, Adam Laponis, sold 1,965 shares of common stock on 2026-08-21 at $139.066 per share. The company states these shares were sold to cover tax withholding obligations upon vesting of Restricted Stock Units, under a mandated "sell to cover" arrangement rather than a discretionary trade. After this tax-related sale, Laponis directly holds 108,633 shares of Twist Bioscience common stock, which include shares acquired through the company’s Employee Stock Purchase Plan.
Twist Bioscience Corp (TWST) reported that Chief Executive Officer and director Emily M. Leproust sold 6,639 shares of common stock on August 21, 2026 at $139.066 per share. According to the company’s equity plan, this mandated “sell to cover” transaction was solely to satisfy tax withholding on vested Restricted Stock Units and was not discretionary. Following the sale, she directly held 812,299 common shares. She also holds several employee stock options with exercise prices ranging from $5.95 to $67.85, including performance stock options with an exercise price of $67.85 expiring August 31, 2030 on 64,950 underlying shares.
Twist Bioscience Corp (TWST) reported that Chief Accounting Officer Robert F. Werner sold a total of 1,523 shares of common stock in two transactions on August 21 and 24, 2026. According to the company’s equity incentive plan, these mandated “sell to cover” transactions were executed solely to fund tax withholding on vested Restricted Stock Units and were not discretionary trades.
Twist Bioscience Corp (TWST) reported that officer Robert F. Werner filed a Rule 144 notice covering a proposed sale of 854 shares of common stock through Fidelity Brokerage Services LLC on or after August 24, 2026, on NASDAQ. The shares relate to restricted stock vesting, and the sale includes an amount to cover a tax obligation from a vested equity award distribution. Werner also reported several prior common stock sales over the preceding three months.
Twist Bioscience Corp (TWST) reported that Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary, sold 14,205 shares of common stock on August 19, 2026, at $129.75 per share in an open-market or private transaction. Following the sale, he directly holds 75,661 shares. The transaction was effected under a previously adopted Rule 10b5-1 trading plan dated February 17, 2026.